ALAMEDA, Calif., Feb. 11, 2009 (GLOBE NEWSWIRE) -- Avigen, Inc. (Nasdaq:AVGN), a biopharmaceutical company, today reported financial results for its fourth quarter and year ended December 31, 2008. At December 31, 2008, Avigen had approximately $57 million in financial assets, including cash, cash equivalents, and available-for-sale securities and restricted investments, compared with approximately $78 million at December 31, 2007. More complete financial results are detailed in the financial tables below.
